Pattern of Growth and Characteristics of Down Syndrome Pediatrics Patients

NCT05056285 | Unknown

• 1 other identifier: PogacoDsppaAuch
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Down syndrome or Down's syndrome (DS), also known as trisomy 21, is a genetic disorder caused by the presence of all or part of a third copy of chromosome 21. It is usually associated with physical growth delays, mild to moderate intellectual disability, and characteristic facial features. The parents of the affected individual are usually genetically normal. The probability increases from less than 0.1% in 20-year-old mothers to 3% in those of age 45 .

Conditions

Growth Disorders

Outcome Measures

Primary Outcomes (1)

• The pattern of growth in Down syndrome patients

  Descriptive case series study

  6 months

Study Arms (1)

Down syndrome less than four years Group

Eligibility Criteria

• Age: Up to 4 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Probability Sample

Study Population

1. Inclusion criteria: All Down syndrome children attending Assuit university less than four years with or without cardiovascular . 2. Exclusion criteria: Any Down syndrome child more than four years. This is a descriptive case series study.

You may qualify if:

• All Down syndrome children attending Assuit university less than four years with or without cardiovascular.

You may not qualify if:

• Any Down syndrome child more than four years.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (7)

• Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen. 2002;9(1):2-6. doi: 10.1136/jms.9.1.2.

  PMID: 11943789 BACKGROUND

• Perkins JA. Overview of macroglossia and its treatment. Curr Opin Otolaryngol Head Neck Surg. 2009 Dec;17(6):460-5. doi: 10.1097/MOO.0b013e3283317f89.

  PMID: 19713845 BACKGROUND

• Malt EA, Dahl RC, Haugsand TM, Ulvestad IH, Emilsen NM, Hansen B, Cardenas YE, Skold RO, Thorsen AT, Davidsen EM. Health and disease in adults with Down syndrome. Tidsskr Nor Laegeforen. 2013 Feb 5;133(3):290-4. doi: 10.4045/tidsskr.12.0390. English, Norwegian.

  PMID: 23381164 BACKGROUND

• Sara VR, Gustavson KH, Anneren G, Hall K, Wetterberg L. Somatomedins in Down's syndrome. Biol Psychiatry. 1983 Jul;18(7):803-11. No abstract available.

  PMID: 6225471 BACKGROUND

• Piro E, Pennino C, Cammarata M, Corsello G, Grenci A, Lo Giudice C, Morabito M, Piccione M, Giuffre L. Growth charts of Down syndrome in Sicily: evaluation of 382 children 0-14 years of age. Am J Med Genet Suppl. 1990;7:66-70. doi: 10.1002/ajmg.1320370712.

  PMID: 2149977 BACKGROUND

• Patterson D. Molecular genetic analysis of Down syndrome. Hum Genet. 2009 Jul;126(1):195-214. doi: 10.1007/s00439-009-0696-8. Epub 2009 Jun 13.

  PMID: 19526251 RESULT

• Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. Eur J Pediatr. 2010 Dec;169(12):1445-52. doi: 10.1007/s00431-010-1253-0. Epub 2010 Jul 15.

  PMID: 20632187 RESULT

MeSH Terms

Conditions

Growth Disorders

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Dalia Galal Mahran, Professor

CONTACT

01007120821; daliaym2001@yahoo.com

Hekma Saad Farghaly, Professor

CONTACT

01091251040; hekmafarghly73@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Amira Gaber Osman

Study Record Dates

• First Submitted: September 15, 2021
• First Posted: September 24, 2021
• Study Start: October 1, 2021
• Primary Completion: March 31, 2022
• Study Completion: April 30, 2022
• Last Updated: September 24, 2021

Record last verified: 2021-09